FI965224A - Polynukleotidirokote papilloomavirukselle - Google Patents

Polynukleotidirokote papilloomavirukselle Download PDF

Info

Publication number
FI965224A
FI965224A FI965224A FI965224A FI965224A FI 965224 A FI965224 A FI 965224A FI 965224 A FI965224 A FI 965224A FI 965224 A FI965224 A FI 965224A FI 965224 A FI965224 A FI 965224A
Authority
FI
Finland
Prior art keywords
pct
sec
papillomavirus
papilloma virus
date
Prior art date
Application number
FI965224A
Other languages
English (en)
Swedish (sv)
Other versions
FI965224A0 (fi
Inventor
John J Donnelly
Margaret A Liu
Douglas Martinez
Donna Mont-Gomery
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of FI965224A publication Critical patent/FI965224A/fi
Publication of FI965224A0 publication Critical patent/FI965224A0/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
FI965224A 1994-06-30 1996-12-27 Polynukleotidirokote papilloomavirukselle FI965224A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26842494A 1994-06-30 1994-06-30
PCT/US1995/006915 WO1996000583A1 (en) 1994-06-30 1995-06-01 Polynucleotide vaccine for papillomavirus

Publications (2)

Publication Number Publication Date
FI965224A true FI965224A (fi) 1996-12-27
FI965224A0 FI965224A0 (fi) 1996-12-27

Family

ID=23022939

Family Applications (1)

Application Number Title Priority Date Filing Date
FI965224A FI965224A0 (fi) 1994-06-30 1996-12-27 Polynukleotidirokote papilloomavirukselle

Country Status (20)

Country Link
US (1) US5866553A (fi)
EP (1) EP0768893B1 (fi)
JP (1) JPH10501987A (fi)
CN (1) CN1156966A (fi)
AT (1) ATE233101T1 (fi)
AU (1) AU701973B2 (fi)
CA (1) CA2193365C (fi)
CZ (1) CZ375296A3 (fi)
DE (1) DE69529748T2 (fi)
ES (1) ES2191052T3 (fi)
FI (1) FI965224A0 (fi)
HU (1) HU220747B1 (fi)
IL (1) IL113817A (fi)
MX (1) MX9700229A (fi)
NO (1) NO965590L (fi)
NZ (1) NZ288045A (fi)
PL (1) PL180639B1 (fi)
SK (1) SK164196A3 (fi)
WO (1) WO1996000583A1 (fi)
ZA (1) ZA954641B (fi)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6995008B1 (en) * 1994-03-07 2006-02-07 Merck & Co., Inc. Coordinate in vivo gene expression
US5736524A (en) * 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
FR2751879B1 (fr) * 1996-07-30 1998-10-30 Transgene Sa Composition pharmaceutique contre les tumeurs et infections a papillomavirus
US7118754B1 (en) 1996-07-30 2006-10-10 Transgene S.A. Pharmaceutical composition for treating papillomavirus tumors and infection
DE19631357A1 (de) * 1996-08-02 1998-02-05 Deutsches Krebsforsch Vektor zur Aktivierung des Immunsystems gegen mit Papillomviren bzw. Sequenzen davon assoziierten Zellen
US20060002949A1 (en) * 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6797276B1 (en) * 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US20060002959A1 (en) * 1996-11-14 2006-01-05 Government Of The United States Skin-sctive adjuvants for transcutaneous immuization
AU722326B2 (en) * 1997-02-14 2000-07-27 Merck & Co., Inc. Polynucleotide vaccine formulations
US6183746B1 (en) 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6013258A (en) * 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US20040258703A1 (en) * 1997-11-14 2004-12-23 The Government Of The Us, As Represented By The Secretary Of The Army Skin-active adjuvants for transcutaneous immunization
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
AU3489499A (en) * 1998-04-14 1999-11-01 Merck & Co., Inc. Needleless administration of polynucleotide formulations
ATE369428T1 (de) * 1998-09-04 2007-08-15 Sanofi Pasteur Ltd Behandlung von gebärmutterhalskrebs
US20020054914A1 (en) * 1999-02-03 2002-05-09 Tulin Morcol Compositions and methods for therapuetic agents complexed with calcium phosphate and encased by casein
US20040258763A1 (en) * 1999-02-03 2004-12-23 Bell Steve J.D. Methods of manufacture and use of calcium phosphate particles containing allergens
EP1150918B1 (en) 1999-02-03 2004-09-15 Biosante Pharmaceuticals, Inc. Method of manufacturing therapeutic calcium phosphate particles
ATE549032T1 (de) * 1999-03-26 2012-03-15 Vical Inc Adjuvanzverbindungen zur verbesserung von immunreaktionen auf polynukleotid-basierten impfstoffen
EP1165132B1 (en) * 1999-04-08 2011-10-19 Intercell USA, Inc. Dry formulation for transcutaneous immunization
PT1212358E (pt) * 1999-08-25 2005-04-29 Merck & Co Inc Genes sinteticos de papilomavirus humano
US7001995B1 (en) 1999-08-25 2006-02-21 Merck & Co., Inc. Synthetic human papillomavirus genes
KR100366608B1 (ko) * 2000-02-15 2003-01-09 마스터진(주) 형질전환 식물체로부터 생산된 재조합 인간 파필로마바이러스 백신
US20020044948A1 (en) * 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
SE0002498D0 (sv) * 2000-07-03 2000-07-03 Stefan Schwartz Papillomavirus vaccine
KR20020005332A (ko) * 2000-07-10 2002-01-17 정상훈 탈모증 치료용 키트
CA2437899C (en) * 2001-02-13 2012-05-15 Gregory M. Glenn Vaccine for transcutaneous immunization against etec-caused traveler's diarrhea
EP1409012B1 (en) * 2001-06-22 2009-02-11 The Wistar Institute Of Anatomy And Biology Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein
DE10137102A1 (de) * 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
US20030185892A1 (en) * 2001-08-17 2003-10-02 Bell Steve J. D. Intraocular delivery compositions and methods
US20030228327A1 (en) * 2001-11-05 2003-12-11 Lasher Alfred W. DNA-based plasmid formulations and vaccines and prophylactics containing the same
DK1585812T3 (en) 2002-12-13 2017-04-10 Alphavax Inc MULTI-ANTI-ANTI-ANTI-VIRUS REPLICATE PARTICLES AND PROCEDURES
WO2005084637A2 (en) * 2004-02-13 2005-09-15 Nod Pharmaceuticals, Inc. Particles comprising a core of calcium phosphate nanoparticles, a biomolecule and a bile acid, methods of manufacturing, therapeutic use thereof
CA2586035A1 (en) 2004-11-01 2006-05-11 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles in use for aesthetic or cosmetic medicine, and methods of manufacture and use
CN101193653B (zh) * 2005-02-01 2013-03-27 美国政府健康及人类服务部 用于诱导广泛交叉中和抗体的乳头瘤病毒l2 n末端肽
BRPI0811016B1 (pt) * 2007-04-29 2021-09-21 Xiamen Innovax Biotech Co., Ltd. Proteína li truncada do papiloma vírus humano tipo 16
WO2008134935A1 (fr) 2007-04-29 2008-11-13 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Protéines 18 l1 de type papillomavirus humain tronqué
WO2008145021A1 (en) * 2007-05-29 2008-12-04 Xiamen University A truncated l1 protein of human papillomavirus 6
CN105209063A (zh) * 2013-03-15 2015-12-30 宾夕法尼亚大学理事会 具有抗原和作为佐剂的白细胞介素-23的疫苗

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4497796A (en) * 1980-03-26 1985-02-05 The Regents Of The University Of California Gene transfer in intact mammals
WO1986005816A1 (en) * 1985-04-04 1986-10-09 Georgetown University Type-specific papillomavirus dna sequences and peptides
US4777239A (en) * 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus
DE69032284T2 (de) * 1989-03-21 1998-10-08 Vical, Inc., San Diego, Calif. Expression von exogenen polynukleotidsequenzen in wirbeltieren
EP1471147A3 (en) * 1991-07-19 2007-03-21 The University Of Queensland Method of making a recombinant molecule for the expression of HPV-16 L1 protein
US5376542A (en) * 1992-04-27 1994-12-27 Georgetown University Method for producing immortalized cell lines using human papilluma virus genes
ES2201055T3 (es) * 1992-08-07 2004-03-16 Wyeth Vacunas de adenovirus recombinante.
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization

Also Published As

Publication number Publication date
ES2191052T3 (es) 2003-09-01
NZ288045A (en) 1998-08-26
PL180639B1 (pl) 2001-03-30
HU9603562D0 (en) 1997-02-28
HU220747B1 (hu) 2002-05-28
US5866553A (en) 1999-02-02
MX9700229A (es) 1997-04-30
IL113817A (en) 2001-03-19
DE69529748T2 (de) 2003-10-16
WO1996000583A1 (en) 1996-01-11
EP0768893A1 (en) 1997-04-23
ZA954641B (en) 1996-01-26
DE69529748D1 (de) 2003-04-03
IL113817A0 (en) 1995-08-31
SK164196A3 (en) 1997-08-06
CN1156966A (zh) 1997-08-13
EP0768893B1 (en) 2003-02-26
AU701973B2 (en) 1999-02-11
NO965590L (no) 1997-02-28
ATE233101T1 (de) 2003-03-15
CZ375296A3 (en) 1997-08-13
AU2694595A (en) 1996-01-25
JPH10501987A (ja) 1998-02-24
HUT76446A (en) 1997-09-29
CA2193365A1 (en) 1996-01-11
PL317874A1 (en) 1997-04-28
NO965590D0 (no) 1996-12-27
CA2193365C (en) 2007-04-03
FI965224A0 (fi) 1996-12-27

Similar Documents

Publication Publication Date Title
FI965224A (fi) Polynukleotidirokote papilloomavirukselle
DE69536039D1 (de) Wirtszelle enthaltend ein rekombinantes Virus, welches ein Antigen exprimiert und ein rekombinantes Virus, welches ein immunstimulatorisches Molekül exprimiert
YU12894A (sh) Farmaceutski preparat na bazi nukleinske kiseline
IL134392A0 (en) Vaccine against hpv
TR200001835T2 (tr) Aşı.
ATE326479T1 (de) Varianten von antigenen des menschlichen papillomvirus
WO1996010419A3 (en) Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule
ES2178657T3 (es) Derivados lipopeptidos, procedimiento para su preparacion y su empleo.
FI960977A (fi) Bakteeriperäiset eksportoidut proteiinit ja niihin perustuvat asellulaariset rokotteet
DE59610632D1 (de) Varianten des humanen rekombinanten interferon-gamma (rhu-ifn-gamma) mit erhöhter thermischer stabilität
MXPA03009763A (es) Vacuna contra el virus de la enfermedad de la fiebre aftosa.
SI1196129T1 (sl) Farmacevtski in kozmeticni sestavki, ki obsegajo derivate urokaninske kisline kot odstranjevalce radikalov ali antioksidante
TR200400907T4 (tr) Beta D 5-Tiyoksiloz türevleri, bunları hazırlama yöntemi ve bunların terapötik kullanımları
AU6722498A (en) Disubstituted biphenyloxazolines
ES2095058T3 (es) Derivados del 3-azabiciclo(3.2.0)heptano substituidos como productos intermedios.
SE9401596D0 (sv) New compounds
NZ334582A (en) Polyprotein construct of a papillomavirus